Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.
NACompletedINTERVENTIONAL
Enrollment
35
Participants
Timeline
Start Date
September 30, 2007
Study Completion Date
August 31, 2011
Conditions
Major Depressive Disorder
Interventions
DRUG
sertraline
DRUG
triiodothyronine (T3)
DRUG
reboxetine
Trial Locations (1)
Unknown
Hadassah Medical Organization, Jerusalem
All Listed Sponsors
lead
Hadassah Medical Organization
OTHER
NCT00421369 - Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. | Biotech Hunter | Biotech Hunter